Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H21/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/086889METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND INFECTIOUS DISEASES
WO 06.05.2021
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/057619 Applicant CHINOOK THERAPEUTICS, INC. Inventor DESBIEN, Anthony Lloyd
The present invention relates to methods and compositions for the treatment of diseases with STING agonists. As described hereinafter, STING activation can be modulated to induce local versus systemic immune activation. At lower doses, intratumoral dosing of STING agonists can produce a robust tumor-specific T-cell response capable of ablating a target tumor at a site distal to the STING agonist administration. At higher doses, the distal anti-tumor response is reduced, and ablation of tumor-draining lymph nodes is observed. It is possible to inhibit this ablation of the tumor-draining lymph nodes by co-administration of a TNF antagonist. This co-administration of STING agonists and TNF antagonists can permit the administration of either increased concentrations of STING agonist or STING agonists having greater activity, while maintaining effective tumor control and generation of an anti-tumor adaptive immune response.
2.WO/2021/087431GOLD NANOPARTICLES/NANOSHELLS IMMUNE CONJUGATES FOR ENHANCED IMMUNOTHERAPY AND PHOTOTHERMAL THERAPY FOR HEMATOLOGIC MALIGNANCIES
WO 06.05.2021
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Appl.No PCT/US2020/058474 Applicant NORTHWESTERN UNIVERSITY Inventor LIN, Adam, Y.
Disclosed herein are CpG conjugated nanoparticles for immunotherapy and photothermal therapy. The composition comprises class B CpG conjugated nanoparticles and/or a class C CpG conjugated nanoparticles where the class B CpG conjugated nanoparticles comprises a nanoparticle core and a class B CpG conjugated thereto and the class C CpG conjugated nanoparticles comprises a nanoparticle core and a class C CpG conjugated thereto.
3.20210130823COMPOSITIONS AND METHODS
US 06.05.2021
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No 16910727 Applicant Ionis Pharmaceuticals, Inc. Inventor Thazha P. Prakash

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

4.WO/2021/087440FIBROBLAST-BASED THERAPY FOR TREATMENT OF SCLEROSING CHOLANGITIS
WO 06.05.2021
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
Appl.No PCT/US2020/058500 Applicant FIGENE, LLC Inventor ICHIM, Thomas
In some aspects, disclosed herein are methods and compositions for treatment of sclerosing cholangitis using fibroblasts or derivatives thereof. The disclosed compositions include fibroblasts, engineered fibroblasts, exosomes obtained from fibroblasts, and conditioned media derived from fibroblasts. Methods of the present disclosure include providing fibroblasts to a subject to treat sclerosing cholangitis in the subject. Fibroblasts of the disclosure include fibroblasts capable of reducing inflammation in a subject. In certain aspects, fibroblasts are cultured with activating agents prior to therapeutic administration.
5.2822584Inducción de dinucleótidos cíclicos del interferón tipo I
ES 04.05.2021
Int.Class A61K 31/7084
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
Appl.No 14791304 Applicant The Regents of the University of California Inventor VANCE, Russell E.
6.WO/2021/080021METHOD FOR PRODUCING OLIGONUCLEOTIDE
WO 29.04.2021
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
Appl.No PCT/JP2020/040096 Applicant NITTO DENKO CORPORATION Inventor IWAMOTO, Masafumi
The purpose of the present invention is to provide a method for producing an oligonucleotide and to provide an activating agent for producing the oligonucleotide. The aforementioned problem is solved by a method for producing an oligonucleotide, wherein said method comprises a step in which a nucleoside phosphoramidite having a protective group linked to a hydroxyl group at position 5’ and a nucleoside having an unprotected hydroxyl group at the 3’ position and the 5’ position are reacted in the presence of an activating agent represented by formula (I).
7.WO/2021/081374METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT COMPRESSED SCREENING FOR THERAPEUTICS
WO 29.04.2021
Int.Class G16C 20/30
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
20Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
30Prediction of properties of chemical compounds, compositions or mixtures
Appl.No PCT/US2020/057131 Applicant MASSACHUSETTS INSTITUTE OF TECHNOLOGY Inventor MEAD, Benjamin
Described in certain example embodiments herein are systems, methods, and uses thereof for high-throughput in vitro evaluating multiple test compounds in parallel for biological or pharmacological functions. In certain embodiments, the system allows the selection of a subset of test compounds from a group of test compounds to form an optimized pool, and methods are provided to use such optimized pool of test compounds to identify and validate therapeutic agents for treating diseases and driving guided differentiation of stem cells into desired types of cells. The systems described herein can provide, for example, a cost- effective and high-quality high-throughput approach for drug screening.
8.20210115107METHODS OF TREATMENT USING CTLA4 MOLECULES
US 22.04.2021
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
Appl.No 16953474 Applicant Bristol-Myers Squibb Company Inventor Robert James Peach

The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

9.WO/2021/077110BIOMATERIAL SENSOR SYSTEMS
WO 22.04.2021
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
Appl.No PCT/US2020/056377 Applicant THE REGENTS OF THE UNIVERSITY OF MICHIGAN Inventor MORRIS, Aaron
Provided herein is a biomaterial comprising a sensor system comprising a donor fluorophore linked to a target binding moiety (TBM) and an acceptor molecule linked to a TBM, wherein, when the TBM linked to the donor fluorophore and the TBM linked to the acceptor molecule binds to a target, a resonance energy transfer (RET; e.g., Forster (or Fluorescence) resonance energy transfer (FRET), bioluminescent resonance energy transfer (BRET), chemiluminescent resonance energy transfer (CRET), or a combination thereof) from the donor fluorophore to the acceptor molecule occurs and a detectable signal is produced. An medical device, e.g., an implant, comprising the presently disclosed biomaterial comprising a sensor system is further provided. Related medical devices and solid supports are furthermore provided herein. Use of the biomaterials and medical devices in methods of determining a level of expression of a gene, an RNA, or a protein, is additionally provided.
10.112675063一种含PDRN的嫩肤抗皱组合物及其应用
CN 20.04.2021
Int.Class A61K 8/60
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
60Sugars; Derivatives thereof
Appl.No 202011608185.6 Applicant 王超云 Inventor 王超云
本发明公开了一种含PDRN的嫩肤抗皱组合物及其应用,嫩肤抗皱组合物包括PDRN(多聚脱氧核糖核苷酸)、二肽二氨基丁酰苄基酰胺二乙酸盐与乙酰四肽‑5。PDRN、二肽二氨基丁酰苄基酰胺二乙酸盐与乙酰四肽‑5的质量比为(0.1~3):(1~3):(1~5)。将上述嫩肤抗皱组合物应用于抗皱化妆品中。本发明的组合物协同作用,可降低氧化应激损伤、提高细胞活性、保留水分,刺激胶原、弹性蛋白生成,达到抵抗皱纹的功效。本发明的配方没有常规的副作用,安全无刺激,适合各种肤质的人群,本发明的配方可应用于抗皱类医疗护肤产品。